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Characterization of Mucosal Dysbiosis of Early Colonic
Neoplasia
Bo-young Hong1*, Takayasu Ideta2, Bruno S. Lemos2, Yuichi Igarashi2, Yuliana Tan2, Michael DiSiena3, Allen Mo2, John W. Birk3,
Faripour Forouhar4, Thomas J. Devers2, George M. Weinstock 1* and Daniel W. Rosenberg2*
Aberrant crypt foci (ACF) are the earliest morphologically identifiable lesions in the colon that can be detected by high-definition
chromoendoscopy with contrast dye spray. Although frequently associated with synchronous adenomas, their role in colorectal
tumor development, particularly in the proximal colon, is still not clear. The goal of this study was to evaluate the profile of colon-
adherent bacteria associated with proximal ACF and to investigate their relationship to the presence and subtype of synchronous
polyps present throughout the colon. Forty-five subjects undergoing a screening or surveillance colonoscopy were included in this
retrospective study. Bacterial cells adherent to the epithelia of ACF and normal mucosal biopsies were visualized by in situ
hybridization within confocal tissue sections. ACF showed significantly greater heterogeneity in their bacterial microbiome profiles
compared with normal mucosa. One of the bacterial community structures we characterized was strongly correlated with the
presence of synchronous polyps. Finally, using DNA mass spectrometry to evaluate a panel of colorectal cancer hotspot mutations
present in the ACF, we found that three APC gene mutations were positively associated with the presence of Instestinibacter sp.,
whereas KRAS mutations were positively correlated with Ruminococcus gnavus. This result indicates a potential relationship
between specific colon-associated bacterial species and somatically acquired CRC-related mutations. Overall, our findings suggest
that perturbations to the normal adherent mucosal flora may constitute a risk factor for early neoplasia, demonstrating the
potential impact of mucosal dysbiosis on the tissue microenvironment and behavior of ACF that may facilitate their progression
towards more advanced forms of neoplasia.
npj Precision Oncology            (2019) 3:29 ; https://doi.org/10.1038/s41698-019-0101-6
INTRODUCTION
Colorectal cancer (CRC) is the third leading cause of cancer-related
deaths in the United States. Fortunately, the widespread applica-
tion of screening colonoscopy, together with the identification
and removal of precancerous polyps, has led to a significant
overall reduction in CRC incidence.1–3 Despite the overall health
benefits, endoscopic surveillance has failed to uniformly prevent
the occurrence of CRC, particularly in the proximal colon.4 These
limitations are underscored by patients who develop “interval”
CRC between screening colonoscopies and subsequent surveil-
lance. Most of these cases have been attributed to non-detected
or incompletely resected proximal colon lesions that were initially
present during the index colonoscopy.5–8 Thus, there is a need to
develop more robust strategies that enable the accurate
identification and removal of proximal colon lesions, and,
importantly, to enable the identification of those individuals at
increased risk for recurrent neoplasms at the time of index
colonoscopy.9
Aberrant crypt foci (ACF) are the earliest morphologically
detectable lesions that are frequently present in the colon.9
However, ACF are not routinely detected during conventional
colonoscopy due to their diminutive size (<5mm in diameter).10–14
Despite evidence that ACF are often associated with the presence
of adenomas, their role in tumor development, particularly in the
proximal colon, is still actively debated.15–18 Our laboratory has
recently demonstrated the power of high-definition chromoendo-
scopy to identify colonic ACF within the proximal colon.19 We
further validated an ultra-sensitive DNA mass spectrometry plat-
form that, combined with laser-capture microdissection, enables
the detection of somatic mutations across a wide panel of CRC-
related oncogenes and tumor suppressor genes.9,19 We believe
these recent studies, including our genome-wide methylation
analysis of ACF,20 firmly establish the premalignant potential of ACF
and their potential application to risk prediction. In particular, we
have focused on proximal colon ACF, which we believe may harbor
greater premalignant potential.9,19
During the past two decades, there has been a growing
appreciation for the role of the gut microbiome in CRC
pathogenesis.21 Fusobacterium nucleatum was identified as an
abundant taxon from colorectal tumor tissues, whereas other
species were also detected.22,23 Escherichia coli has also been
associated with CRC. Colonic biopsies of adenomas and CRCs
showed the increased presence of intracellular E. coli,24 whereas
higher abundance of other bacterial species of the phylum
Proteobacteria were found in rectal adenomas.25 Enterohemor-
rhagic E. coli and enteropathogenic E. coli are also known to be
risk factors for CRC, most likely by generating toxins that affect
colonic tissue.26,27 Toxin-producing Bacteroides fragilis can impact
colorectal carcinogenesis by its production of B. fragilis toxin,
resulting in the disruption of E-cadherin junctions, β-catenin
signaling, and interleukin-8 expression.28,29
Our understanding of the characteristics of the colon-associated
microbiome and its potential role in the development of early
colonic neoplasia remain incomplete. The objective of this study is
to characterize the microbiota directly associated with proximal
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colon ACF. Our long-term goal is to determine whether the
microbiome can influence the microenvironment and behavior of
early colonic neoplasia, either facilitating (or impeding) the
progression of small lesions to more advanced forms of neoplasia.
RESULTS
Description of Clinical and Demographic Information
For this study, we retrospectively selected a total of 45 patients
who had undergone a routine screening colonoscopy at the John
Dampsey Hospital (JDH). We assigned the patient samples to the
following three experimental groups: Group I (n= 16 patients) had
no identifiable lesions (ACF or polyps) present in the proximal
colon; Group II (n= 14) had at least one proximal ACF detected at
colonoscopy, but no synchronous polyps; Group III (n= 15) had at
least one or more proximal ACF and synchronous polyp(s)
detected at the time of colonoscopy (Supplementary Table 1).
The characteristics of the study population are shown in Table 1.
Direct visualization of colon-associated bacteria in the colonic
mucosa
ACF, adjacent normal mucosa, and synchronous polyps (tubular
adenomas, hyperplastic polyps (HPs), and sessile serrated
adenoma polyps (SSA/P)) in Group III were directly examined for
the presence of adherent bacteria using 16S universal fluores-
cence in situ hybridization (FISH) probes. Representative lesions
are shown in Fig. 1 (ACF and adjacent normal) and also in
Supplementary Fig. 1 (synchronous polyps identified in Group III).
Bacteria were observed within the mucous layer (green; mucin-2
positive) of the colonic epithelial lining in normal, ACF, and polyp
tissues. However, in no cases did we observe bacterial infiltration
beyond the mucosal layer and into the colonic epithelial lining,
nor within the stroma (Fig. 1 and Supplementary Fig. 1). In
addition, colon-associated bacteria showed no detectable differ-
ences morphologically.
Analysis of Proximal ACF and Colon-Associated Microbiome
Illumina sequencing of the V4 hypervariable region of 16S rRNA
amplicons from all individual samples yielded 7,469,049 raw reads
and 4,414,345 reads after pre-processing of the data set. The
sequence counts per sample ranged from ~5627 to 319,577 reads.
Libraries were normalized by random sub-sampling for compar-
isons across the samples. In total, 815 operational taxonomic units
(OTUs) were found at a 97% identity cutoff from 74 samples. In
order to determine α- and β-diversity, we compared the adherent
bacteria of ACF with adjacent normal colonic mucosa from
patients with or without polyps, separately. We also compared
adherent bacteria of ACF with the normal colonic mucosa of 16
control patients who had no detectable proximal ACF.
First, α-diversity analysis (Supplementary Fig. S2A) showed a
mean richness of 106, 111.9, 105, 131.6, and 120.2 in the normal
mucosa from Group I, normal mucosa from Group II, a proximal
ACF from Group II, normal mucosa from Group III, and a proximal
ACF from Group III, respectively. Proximal ACF lesions and
adjacent normal mucosa from patients with synchronous polyp
(s) showed median richness of 103.3 and 99.6 distinct bacterial
taxa, respectively. These results were slightly lower than median
richness of 110 bacterial taxa found in normal mucosa from the
lesion-free patients. However, there was no statistically significant
difference in bacterial richness between these groups. In addition,
diversity and evenness of the bacterial community within each
sample showed no statistically significant differences (Supple-
mentary Fig. S2B, C). Nonetheless, subject variability of the
bacterial microbiome in lesions from patients with a polyp was
consistently greater than lesion-free patients for richness,
diversity, and evenness.
Next, we characterized the bacterial community structure of
ACF biopsies taken from the proximal colon with or without
synchronous polyp(s) (Fig. 2). Pairwise comparison of bacterial
community structure based on the thetaYC index, which takes into
account membership of taxa and their relative abundance, was
measured between samples. Bacterial community structure
visualized in principal coordinates analysis (PCoA) plots showed
no distinct clustering of proximal ACF compared with their normal
adjacent mucosa or normal mucosa from ACF lesion-free patients
Table 1. Clinical and demographic characteristic of subjects included in the study
Demographics Normal ACF only ACF+ Polyp
Sample size 16 (35.5) 14 (31.1) 15 (33.3)
Age 55.9 ± 9.9 55.9 ± 7.5 57.5 ± 7.7
Male 8 (50.0) 3 (21.4) 8 (53.3)
BMI (kg/m2) 30.0 ± 7.0 29.5 ± 6.7 30.9 ± 6.8
Caucasian 9 (56.3) 10 (71.4) 14 (93.3)
African American 7 (43.8) 4 (28.6) 1 (6.7)
Smoking history 9 (56.3) 6 (42.9) 9 (60.0)
Current smoker 3 (18.8) 2 (14.3) 3 (20.0)
Family history of colon cancer 5 (31.3) 6 (42.9) 3 (20.0)
Diabetes 4 (25.0) 3 (21.4) 2 (13.3)
Daily aspirin (325mg) use 5 (31.3) 3 (21.4) 5 (33.3)
Daily baby Aaspirin (81mg) use 6 (37.5) 4 (28.6) 6 (40.0)
Regular other NSAIDs use 5 (31.3) 8 (57.1) 7 (46.7)
Regular multivitamin use 9 (56.3) 9 (64.3) 4 (26.7)
Regular folic acid use 3 (18.8) 1 (7.1) 1 (6.7)
Regular calcium use 3 (18.8) 6 (42.9) 3 (20.0)
Regular vitamin D use 3 (18.8) 1 (42.9) 7 (46.7)
Antibiotics use (within 1 month) 1 (6.3) 1 (7.1) 0 (0.0)
Values are means ± SD or n (%)
Bo-young Hong et al.
2
npj Precision Oncology (2019)    29 Published in partnership with The Hormel Institute, University of Minnesota
1
2
3
4
5
6
7
8
9
0
()
:,;
(p= 0.139) (Fig. 2a). However, there was a trend observed in which
control mucosal samples (blue) clustered more tightly than ACF
samples (red) or their adjacent normal mucosa (yellow), suggest-
ing that normal mucosa is somewhat more homogeneous in
community structure between samples than the ACF lesions in
terms of bacterial diversity (Fig. 2a). Furthermore, we confirmed
that the distance measured from pairwise thetaYC dissimilarity
comparisons between every sample in proximal ACF (purple) and
their adjacent normal mucosa (green) were both significantly
different from that of control normal mucosa (blue) (p < 0.0001,
p= 0.008) (Fig. 2b), indicating that ACF patients harbor a
significantly more heterogeneous bacterial structure than control
subjects with no detectable lesions. These results indicate that
bacterial community structure has been significantly altered in
proximal ACF of Groups II and III.
Next, to determine whether microbiome changes are associated
with an at-risk colon, we analyzed a subset of proximal ACF and
adjacent normal mucosa from patients with synchronous polyp(s).
Interestingly, the PCoA plot showed a clearer tight clustering of
control mucosal samples (blue) from ACF samples (purple) or their
adjacent normal mucosa (green) (p= 0.004) (Fig. 2c). Microbiome
alterations that were observed in proximal ACF samples with
synchronous polyp(s) were greater than those changes found in
ACF samples without synchronous polyps. The thetaYC dissim-
ilarity pairwise comparison between samples confirmed a
significant difference between normal mucosa and proximal ACF
with synchronous polyp(s) (p < 0.0001) (Fig. 2d), implicating
mucosal dysbiosis in the at-risk colon.
Proximal ACF-Adherent Bacterial Taxa are Stratified by
Synchronous Polyps and Somatic Mutations
We further identified differentially abundant specific bacterial taxa
present within ACF lesions from patients with and without
synchronous polyp(s) (Supplementary Fig. S3). The top 15 most
differentially abundant taxa in ACF lesions taken from patients
without synchronous polyps included a significant increase of
Lactonifactor sp. (OTU036) and Pantoea sp. (OTU038), as well as a
significant decrease of Clostridium XIVa sp. (OTU103); however,
each of the 15 taxa yielded a relative abundance of <1%. On the
other hand, the 15 most differentially abundant taxa present in
ACF lesions taken from patients with synchronous proximal polyps
included a significant increase of Eubacterium sp. (OTU060) and
Clostiridium sensu stricto sp. (OTU087). Notably, the levels of
Faecalibacterium sp. (OTU001) were significantly lower in mucosal
samples taken from patients without synchronous polyps
compared with normal mucosa from control subjects.
In the following analysis, we determined whether the presence
of a somatic mutation in proximal ACF may influence the
association and composition of colon-associated bacterial species.
To test this possibility, host DNA was examined by DNA mass
spectrometry analysis using our recently reported customized CRC
mutation panel.9 Patients harboring a somatic mutation to the
tumor suppressor gene, APC (R1450*, R876*, S1465fs*3), showed a
significant correlation with Intestinibacter sp. (p < 0.001). ACF with
a mutation in the proto-oncogene, KRAS (G12V, G12D), showed
a significant correlation with Ruminococcus gnavus (p < 0.001)
(Fig. 3). Although this analysis is limited in sample size, these
results provide the specific indication of a potential relationship
between specific adherent bacterial species and a particular
CRC-related somatic mutation.
Correlation of Proximal ACF Bacterial Communities and Clinical
Parameters
We further investigated the extent to which changes in the
microbiome community signature of proximal ACF may be
associated with polyp incidence SSA/P, HPs or conventional
adenomas. Figure 4 shows ACF bacterial profiles depicted as a
heat map, with gender and body mass index (BMI) of the patients
denoted. Two distinct microbiome clusters segregated by
bacterial community profile were identified in proximal ACF
lesions; 62 samples were present in Microbiome Cluster A and
12 samples were present in Microbiome Cluster B. The presence of
a proximal ACF lesion alone did not distinguish Microbiome
Clusters A and B (p= 0.4089). However, a proximal ACF lesion with
Fig. 1 Direct visualization of tightly colon-associated bacteria within the colonic mucosa. Proximal ACF and adjacent normal mucosa were
directly examined for the presence of colon-associated bacteria using 16S universal FISH probes. Clusters of bacteria were observed within the
mucous layer on epithelium. Red: bacteria (EUB338-cy3 probe), Magenta: E-cadherin, Green; Mucin-2, Blue: DAPI. Bacteria are marked with
white arrows. Bacteria were observed within the mucous layer associated with the epithelium
Bo-young Hong et al.
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or without the presence of a synchronous polyp clearly
distinguished Microbiome Clusters A and B (p < 0.0001), indicating
that a distinct bacterial community composition may be
associated with an at-risk colon. Importantly, >50% of proximal
ACF samples within Microbiome Cluster A occurred in the absence
of synchronous polyps, whereas >90% of proximal ACF samples
within Microbiome Cluster B had at least one synchronous polyp
present in the same subject. The top five differentially abundant
OTUs were taxonomically classified as Clostridium sp., Alistipes
putredinis, Clostridium sp., Bacteroides ovatus, and Anaerostipes
hadrus (Microbiome Cluster A), whereas Sporobacter sp., Oscilli-
bacter sp., Lachnoclostridium sp., Roseburia sp., and Roseburia sp.
are Microbiome Cluster B.
Based on the strong association for the presence of a
synchronous polyp(s) with Microbiome Cluster B, we further
investigated the location and subtype of polyps (Supplementary
Table 2) associated with this microbiome cluster (Fig. 5). Out of the
15 subjects represented within this group (Group III), 1 subject had
a proximal SSA/P, 10 subjects had tubular adenoma(s), and
4 subjects had HPs, whereas 1 sample (Group II) from Microbiome
Cluster B had no evidence of a synchronous polyp. Overall,
Microbiome Cluster B was significantly correlated with the
presence of a colon polyp (p= 0.0073). Furthermore, all normal
mucosal samples were found within Microbiome Cluster A.
Although our sample sizes are somewhat limited, we believe
these results suggest that the Microbiome Cluster B profile may be
associated with the presence of mucosal dysbiosis.
As further shown in Fig. 5, known CRC risk factors, including
gender, obesity, and polyp location were significantly correlated
with Microbiome Cluster B (p= 0.0007, p= 0.0007, p= 0.0073 for
these three risk factors, respectively). These results suggest that
the distinct microbiome clusters observed in this study are in
concordance with a combination of CRC risk factors. Interestingly,
acetaminophen intake was positively correlated with Microbiome
Cluster B (p= 0.0047), whereas calcium consumption was
negatively correlated with Microbiome Cluster B (p= 0.0169). It
is noteworthy that antibiotic intake did not significantly correlate
with either Microbiome Cluster A or B (p= 0.163).
Predictive Metabolic Function
Several functional Kyoto Encyclopedia of Gene and Genomes
(KEGG) pathways of potential clinical significance were predicted
within bacterial communities present between Microbiome
Fig. 2 β-Diversity comparison of the microbiome between normal mucosa and ACF based on thetaYC distance. In polyp-free subjects,
principle coordinate analysis (PCoA) plots showed no significant spatial separation as determined by AMOVA between proximal ACF lesions
and control mucosa taken from both ACF-free control and paired normal samples from the same ACF subject a. The distance measured
pairwise between each sample, however, showed significant differences in microbiome community structure b. In polyp subjects, PCoA plots
showed no significant spatial separation tested using AMOVA between proximal ACF lesions and control mucosa from both ACF-free controls
and paired normal samples taken from the same ACF subject c. However, ACF samples from patients with polyps were better rsolved from
control samples (blue) compared with that in a. In addition, the distance measured pairwise between each sample showed significant
differences in microbiome community structure d, with more significant p-values from b when comparing the ACF site from polyp subjects
(purple) to control group (blue) using Mann–Whitney test
Bo-young Hong et al.
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Clusters A or B (Fig. 6). Microbiome Cluster A showed functional
changes associated with lipid metabolism, amino acid metabo-
lism, nucleic acid metabolism, carbohydrate metabolism, and
metabolism of co-factors and vitamins, as well as DNA replication,
repair, folding, sorting and degradation, and translation. On the
other hand, Microbiome Cluster B was associated with the
following predicted pathways: cell motility, membrane transport,
and signal transduction (Fig. 6).
DISCUSSION
In this study, we characterized the microbiome associated with
early colonic neoplasia. We determined the composition of the
colon-associated microbiome in proximal ACF and its relationship
to the presence of synchronous polyp(s) present within colons of
normal colonoscopy screening subjects. Our long-term goal is to
uncover specific microbiota–epithelial interactions and to further
understand how microbial dysbiosis may impact the microenvir-
onment of the colon. It is likely that specific microbiota–epithelial
interactions may directly influence the growth potential of
proximal colonic ACF. The present study begins to develop a
comprehensive microbiome data set of precancerous lesions
present in the proximal colon, including their histological features
and associated somatic mutations that can be combined with
detailed information on microbial community structure. We
believe this combinatorial approach will enable a sensitive and
comprehensive prediction of early cancer risk and may ultimately
provide new avenues for cancer prevention strategies based upon
the targeted manipulation of the gut microbiota.
F. nucleatum has been identified in a number of studies as one
of the most abundant bacterial species associated with CRC
tumors.22,30–34 Our data indicate that precancerous proximal ACF
also display evidence of dysbiosis of colon-associated mucosal
bacteria. However, the specific taxa shown to be associated with
advanced neoplasia, such as the abovementioned F. nucleatum,
was neither prevalent nor abundant in our sample cohort. We
believe our findings are consistent with those of a study35
showing that F. nucleatum stimulates the growth of colorectal
cancer cells via interactions with the FadA receptor without
directly affecting adenomatous tissue, leading the authors to
speculate that F. nucleatum may provide a “second hit” to the
initiated colonic epithelium. Regardless, our results indicate
significant dysbiosis of mucosal adherent microbiota, with an
increase in presumed pathogens and a decrease in a number of
taxa that may have beneficial properties. This latter group of
microbiota may also include a significant decrease of Faecalibac-
terium prausnitzii, one of the more abundant taxa shown to have
anti-inflammatory activity in the human intestine.36,37 This is also
consistent with a recent meta-analysis of mucosal microbiota, in
which Faecalibacterium was reported to be significantly decreased
in polyp tissues and CRC.38 Overall, our results suggest that
dysbiosis of the colonic mucosal microbiome is associated with
the more advanced forms of colonic neoplasia.
Our results further demonstrate that it is possible to provide a
detailed view of tightly associated microbial composition obtained
from even the smallest mucosal biopsy specimens (~2 mm3), even
after a thorough pre-colonoscopy purging protocol. Although it is
likely to be that luminal bacteria have a more complex community
structure, in this study we have focused exclusively on tightly
adherent mucosal microbiota. Mucosal adherent bacteria are likely
to play a more direct role in the pathogenesis of CRC than luminal
bacteria.39 Thus, we believe that this bacterial pool may provide
greater insight into mucosal-specific colonic neoplasia due to their
close interactions with epithelial and immune cells despite their
lower overall bacterial load and complexity. Our sample set has
readily provided several distinct microbial clusters, referred to as
Microbiome Clusters A and B, showing a clear distinction among
the three groups. Microbiome Cluster B has a particularly strong
association with the presence of synchronous polyps in the colon,
including SSAs, TAs, and HPs. We further identified a group of taxa
strongly associated with Microbiome Cluster A.
Based upon our in silico analyses, we are aware of the relatively
low taxonomic resolution that has resulted from the V4
hypervariable region of the 16S rRNA gene (data not shown). In
fact, many of the OTUs identified by our analysis were classified at
the genus level without inclusion of species names. However, the
present study provides the specific OTU-level bacterial community
analysis associated with early neoplastic changes occurring within
the human colonic mucosa.
Predictive metabolic function analysis demonstrated that the
functional categories associated with Microbiome Cluster B
comprised a group of virulence factors; these include bacterial
motility proteins and additional proteins associated with the two-
component system, secretion system, flagella assembly, and
chemotaxis. These results are consistent with a previous study
that demonstrated many similar predicted metabolic pathways
that were reportedly enriched in colorectal tumors.40 The
metabolic functions represented in Microbiome Cluster B may
implicate bacterial community composition and their biological
markers, and this may further explain the extent of mucosal
dysbiosis uniquely observed in Microbiome Cluster B, even in the
earliest precancerous ACF lesions.
To gain further insight into how these microbial–epithelial
interactions may impact early colonic neoplasia, we performed an
analysis of CRC-related somatic mutations on a subset of laser-
captured ACF samples using our customized CRC somatic
mutation panel and DNA mass spectrometry.9 We found that
Intestinibacter sp. and R. gnavus are strongly associated with the
Fig. 3 Significantly abundant bacterial taxa by DNA mutation types. Intestinibacter sp. was significantly increased in ACF samples with an APC
mutation, whereas R. gnavus was significantly increased in ACF samples with a KRAS mutation compared with samples with no mutation
detected
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presence of either an APC or KRAS mutation, respectively (Fig. 3).
These results provide what we believe is the direct evidence that
cancer-related somatic mutations present at the earliest stages of
colonic neoplasia may be directly associated with the presence of
specific microbial organisms. Although these findings represent
only a limited sample size, they do raise the possibility of a direct
host–microbial interaction within the colonic mucosa that may
contribute to neoplastic progression, findings we believe warrant
further investigation.
In summary, our study suggests the comprehensive character-
ization of a distinct microbiome profile directly associated with
proximal ACF, the earliest morphologically identifiable lesion in
the colon that likely precedes the formation of more advanced
forms of colonic neoplasia. We believe that our emphasis on the
characteristics of the microbiome during early neoplasia will have
a significant impact in terms of clinical application. Capturing
integrated and combined characteristics of precancerous lesions,
ranging from somatic mutations, histology, and microbiome
composition, will eventually lead to a more sensitive and
comprehensive detection of cancer risk, and contribute to efforts
in cancer prevention and advanced colonoscopy screening based
on the gut microbiome.
METHODS
Study Population and Colonoscopy Procedure
Eligible healthy adults (50–65 years of age) that were referred to the
Division of Gastroenterology at the John Dempsey Hospital/University of
Connecticut Health (Farmington, CT) for screening or surveillance
colonoscopy were recruited to the ACF study by participating physicians
during their initial office consultation. Patients were screened for a
standard-of-care colonoscopy procedure. Mucosal biopsy samples were
procured under strict guidelines approved by the Institutional Review
Board from the University of Connecticut Health Committee (#IE-10-068SJ-
3.2) between 2010 and 2017. All participants provided written informed
consent prior to inclusion in the study. Patients who met the Amsterdam
criteria for familial adenomatous polyposis or hereditary non-polyposis
CRC were excluded. Patients with ulcerative colitis, active infectious
gastroenteritis, proctitis, diseases of malabsorption, or a history of CRC
were also excluded. To limit the confounders of age and smoking, all
subjects selected were non-smokers. Prior to colonoscopy, all participants
completed a study questionnaire, including information on smoking,
current medications and supplement use, previous history of endoscopy,
and family history of cancer. BMI (kg/m2) was calculated from weight (kg)
and height (m) measurements obtained during the initial office
consultation.
High-definition chromoendoscopy was performed in the distal 20 cm
of the colorectum and throughout the entire proximal colon with a
freshly prepared solution of 0.1% indigo carmine dye spray, using a
spray catheter for contrast enhancement. The identification and
histologic evaluation of ACF has been described in our previous
publications.9,41 Proximal ACF were isolated from grossly normal-
appearing colonic mucosa by biopsy in situ and were removed using
biopsy forceps. In addition, each subject had a histologically confirmed
corresponding normal biopsy specimen taken from the same (proximal)
region of the colon, generally within 2 cm of the ACF biopsy sample.
Proximal ACF were identified if two or more crypts had an increased
luminal diameter of 1.5 to 2 times the luminal size of surrounding crypts.
Proximal ACF were visualized, videotaped, and photographed using an
Olympus high-definition colonoscope. Biopsies of individual proximal
ACF and/or normal colonic mucosa were embedded immediately in
optimal cutting temperature (OCT) media and stored at −80 °C until
further analysis. Samples were stained with hematoxylin and eosin, and
ACF and polyps were histologically confirmed by a board-certified
gastrointestinal (GI) pathologist (F.F.).
Fig. 4 Microbiome profiles of the entire sample set. Heat maps were generated using Morpheus based on the top 100 OTUs found in the
biopsy specimens. Samples are shown in columns, while each OTU is depicted in the rows. Only significantly different taxa in each cluster are
shown. The color scale appears on the top right side of the figure. Unsupervised hierarchical clustering (complete linkage) shows two clusters,
Microbiome Cluster A (cyan) and Microbiome Cluster B (magenta). Annotation for the presence of a polyp(s) in the subject, gender, and
obesity, as well as the presence of a polyp(s) in the ascending colon are indicated by unique shapes when positive. Significance was
determined after a Benjamini–Hochberg multiple comparison adjustment
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Confocal Microscopy
Human tissues were stained by fluorescence in situ hybridization using a
16S rRNA probe as previously described.42 Briefly, OCT-embedded tissue
was cryo-sectioned at a 5 µm thickness and then fixed in 4%
paraformaldehyde for 24 h at 4 °C. Formalin-fixed paraffin-embedded
human polyp tissues were de-paraffinized with sequential washes in
xylene and ethanol. Samples were then hybridized using the EUB338-cy3
probe (Eurofins Genomics) at 55 °C overnight. Immunofluorescence was
performed with 5% BSA blocking, followed by staining with anti-Mucin-2
(Santa Cruz Biotechnology) and anti-E-cadherin (Cell Signaling Technology)
at 4 °C overnight. Alexa Fluor 488 (Thermo Fisher) and Alexa Fluor 647
(Thermo Fisher) were used to detect Mucin-2 and E-cadherin, respectively.
Nuclei were stained with 10 µg/mL DAPI (Sigma-Aldrich). Slides were
mounted with Prolong Gold (Invitrogen). Images were taken at ×63/1.4 A
magnification using a ZEISS LSM 880 Confocal Microscope maintained at
the CCAM Microscopy Facility at the University of Connecticut Health
Center. Images were captured with z-stack and 10% overlap tile scanning
to obtain in-depth bacterial localization on each mucosal sample. Finally,
images were processed with ImageJ to generate a final image.
DNA Extraction, 16S rRNA Gene Amplicon Library Construction,
and Sequencing
DNA was extracted from whole tissue biopsies (proximal ACF and adjacent
normal mucosa) using the MoBio PowerMag Soil 96 well kit (MoBio
Laboratories) according to the manufacturer’s protocol for the Eppendorf
epMotion liquid-handling robot. DNA extracts were quantified using the
Quant-iT PicoGreen kit (Thermo Fisher Scientific). The V4 hypervariable
region of the bacterial 16S rRNA gene was amplified using 30 ng of
extracted DNA as a template and the primer set of 515 F and 806 R with
Golay code indices.43 Samples were amplified in triplicate using GoTaq
(Promega) with the addition of 10 µg of BSA (New England BioLabs). The
PCR reaction was incubated at 95 °C for 3.5 min with 30 cycles of 30 s at
95.0 °C, 30 s at 50.0 °C, and 90 s at 72.0 °C, followed by a final extension at
72.0 °C for 10min. PCR products were pooled for quantification and
visualization using the QIAxcel DNA Fast Analysis (Qiagen). PCR products
were normalized based on the concentration of DNA from 250 to 400 bp,
then pooled using the QIAgility liquid-handling robot. The pooled PCR
products were cleaned up using the Mag-Bind RxnPure Plus (Omega Bio-
tek) according to the manufacturer’s protocol. The cleaned pool was
sequenced on the MiSeq (Illumina, Inc.) using the v2 2 × 250 base-pair kit
(Illumina, Inc.). Positive/negative controls were included for DNA extraction
and amplification.
Sequence Data Processing
Raw 16S rRNA gene reads were processed in mothur.44 Sequencing reads
were processed by removing the sequences with low quality (average
quality < 25) and ambiguous bases (N’s). Chimeric amplicons were
removed using UChime software. For 16S, an OTU-based approach was
used by clustering sequences with 3% dissimilarity cutoff in Usearch45 and
the taxonomic classification via the Ribosomal Database Project Classi-
fier.46 Shannon diversity index was calculated for each sample and
visualized using GraphPad Prism software. Significant separation of
microbiome samples based on pairwise thetaYC distance was calculated,
visualized as PCoA plots using R. Hierarchical clustering of ACF and normal
mucosal bacterial communities based on OTU relative abundances was
performed via Jaccard distances and the average linkage method in
Morpheus. RAWGraph was utilized to visualize Microbiome Clusters
A and B.
Predictive Functional Profiling
Predictive functional profiling was performed using a phylogenetic
investigation of communities by reconstruction of unobserved states
(PICRUSt)47 inferred from 16S rRNA gene copies as OTUs. Predicted
functional gene contents or KEGG Orthologs of bacterial communities
were estimated further to predicted functional pathways using “predict_-
metagenomes.py” command of PICRUSt with default parameters. Differen-
tially featured gene function was selected using LEfSe48 with the default
settings. Results were filtered to contain a logarithmic LDA score >2.5.
Fig. 5 Microbiome signature shapes the development of polyps. Two distinct microbiome clusters (Microbiome Clusters A and B) defined by
bacterial community signature were depicted in the Sankey diagram, demonstrating the “flow” of each biopsy sample. Microbiome Cluster B
is associated with precancerous lesions. Over 90% of samples with Microbiome Cluster B yielded malignant polyps in the same subject. Less
than 50% of samples with Microbiome Cluster A were associated with the presence of any polyp in the same subject (Top). Bacterial relative
abundances in each category were depicted in the bar graph comparing groups from the Sankey diagram above. There were bacterial
community differences by Microbiome Cluster type, ACF/polyp status (no lesion, ACF, and ACF with polyp), and the specific type of polyp
present in the subjects. Microbiome Clusters A and B were significantly correlated with demographic or clinical characteristics, such as obesity
status, gender, acetaminophen, and calcium intake. Antibiotic intake was not significantly correlated with Microbiome Clusters A and B
(Table 1)
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Mutation Analysis
The customized DNA mass spectrometry assay design included the
following CRC hotspot somatic mutations: APC_R1450X, APC_S1465fsX3,
APC_R876X, KRAS_G12DV, NRAS_G12D, NRAS_G13D, BRAF_V600E,
ERBB2_G776insYVMA-c2325, and ERBB2_G776insYVMA-c2324.9 Mutation
screening was performed on a fee-for-service basis by the Genomics
Shared Resources Core facility at the Roswell Park Comprehensive Cancer
Center.49 Briefly, the protocol involves PCR amplification of DNA using
single-nucleotide polymorphism-specific primers, followed by a base-
extension reaction using the iPLEX PRO chemistry (Agena Bioscience). The
PCR products were treated with (shrimp alkaline phosphatase, then
temperature-ramped to 85 °C for 5 min to remove excess dNTPs. iPLEX PRO
extension enzyme (Agena) was used for the base-extension reactions. The
final base-extension products were treated with SpectroCLEAN (Agena)
resin to remove contaminating salts. The extension product was spotted
on a 384-pad SpectroCHIP II (Agena) using a Sequenom MassARRAY
Nanodispenser (Agena, San Diego, CA). A MassARRAY Analyzer Compact
MALDI-TOF MS (Agena) was used for data acquisition. All resultant
genotyping calls were performed by the MassARRAY Typer Analyzer
v4.0.26.73 (Agena).
Statistical Analyses
The significance for PCoA plot clustering was tested via analysis of
molecular variance.50 Differentially abundant taxa between ACF and
normal mucosa within subject, across subject, and based upon mutation
subtypes were identified via Wilcoxon’s signed-rank test or the
Mann–Whitney test, as appropriate. All statistical tests were adjusted for
multiple comparisons using the Benjamini–Hochberg false discovery rate
method. Correlations between the sum of relative abundances of
Fig. 6 Predictive functional profiling annotation between Microbiome Clusters A and B. 16S rRNA gene sequencing data were clustered as
OTUs with 97% identity and predictive functional profiling was performed via PICRUSt using KEGG KO as a reference. Several virulence factors
were predicted as functional pathways associated with Microbiome Cluster B (green)
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Microbiome Clusters A or B signature OTUs and clinical parameters were
performed via Spearman’s rank-order tests.
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
DATA AVAILABILITY
Sequence data that support the findings of this study have been deposited in SRA
(PRJNA511474).
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